239 related articles for article (PubMed ID: 33338850)
1. Post-renal transplant malignancies: Opportunities for prevention and early screening.
Turshudzhyan A
Cancer Treat Res Commun; 2021; 26():100283. PubMed ID: 33338850
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
3. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients.
Ho WL; Murphy GM
Br J Dermatol; 2008 Feb; 158(2):217-24. PubMed ID: 18070205
[TBL] [Abstract][Full Text] [Related]
4. Tumours after kidney transplantation.
Lutz J; Heemann U
Curr Opin Urol; 2003 Mar; 13(2):105-9. PubMed ID: 12584469
[TBL] [Abstract][Full Text] [Related]
5. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
6. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
7. Malignancies after pediatric kidney transplantation: more than PTLD?
Mynarek M; Hussein K; Kreipe HH; Maecker-Kolhoff B
Pediatr Nephrol; 2014 Sep; 29(9):1517-28. PubMed ID: 24061645
[TBL] [Abstract][Full Text] [Related]
8. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening.
Asch WS; Bia MJ
Adv Chronic Kidney Dis; 2014 Jan; 21(1):106-13. PubMed ID: 24359993
[TBL] [Abstract][Full Text] [Related]
9. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
Libertiny G; Watson CJ; Gray DW; Welsh KI; Morris PJ
Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
11. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
[TBL] [Abstract][Full Text] [Related]
12. De-novo malignancies after kidney transplantation: A long-term observational study.
Fröhlich FA; Halleck F; Lehner L; Schrezenmeier EV; Naik M; Schmidt D; Khadzhynov D; Kast K; Budde K; Staeck O
PLoS One; 2020; 15(11):e0242805. PubMed ID: 33253202
[TBL] [Abstract][Full Text] [Related]
13. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
14. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
[TBL] [Abstract][Full Text] [Related]
15. Managing the challenge of PTLD in liver and bowel transplant recipients.
Lauro A; Arpinati M; Pinna AD
Br J Haematol; 2015 Apr; 169(2):157-72. PubMed ID: 25377273
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.
Melosky B; Karim M; Chui A; McBride M; Cameron EC; Yeung CK; Landsberg D; Shackleton C; Keown PA
J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S290-4. PubMed ID: 1323341
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
Marcén R
Drugs; 2009 Nov; 69(16):2227-43. PubMed ID: 19852526
[TBL] [Abstract][Full Text] [Related]
19. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
[TBL] [Abstract][Full Text] [Related]
20. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
